Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Start with labs, a medical consultation, and a customized peptide plan
Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma
Information on some other active natural products and derivatives has been summarised in Supplementary materials Table 2
Retatrutide shows potential for greater efficacy through triple-agonism but awaits Phase 3 results Best For Recommendations# Currently Available Treatment# Recommendation : Tirzepatide Reason : FDA-approved and commercially available as Mounjaro/Zepbound with established dosing protocols and post-market safety data Maximum Weight Loss Potential# Recommendation : Retatrutide Reason : Phase 2 data showed 24.2% weight loss at 48 weeks, exceeding tirzepatide's results, though Phase 3 confirmation is pending Non-Alcoholic Fatty Liver Disease# Recommendation : Retatrutide Reason : Glucagon receptor agonism directly promotes hepatic fat oxidation, showing up to 82% liver fat reduction in trials Type 2 Diabetes Management# Recommendation : Tirzepatide Reason : Proven HbA1c reduction with FDA approval specifically for glycemic control in type 2 diabetes Further Reading# Which Is Better For
US$ 25.89
US$ 28.19
US$ 21.03
US$ 23.07
US$ 26.78
US$ 29.78
US$ 21.59
US$ 29.70
US$ 28.19